⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PFE News
Pfizer Inc.
Global Aptamer-Drug Conjugates Market Outlook, 2026-2032 - AI-Enabled Discovery and Precision Delivery Drive Growth Toward USD 2.14 Billion at a 15.79% CAGR
globenewswire.com
ABBV
ADCT
AZN
BMY
GSK
MRK
PFE
ROG
TAK
ZYME
Global Cyclic Peptide Library Market Outlook and Forecast, 2026-2032 - AI-Enabled Discovery Fuels 16.32% CAGR Toward USD 9.86 Billion as PeptiDream, Bicycle Therapeutics, Pfizer and Roche Advance Competition
globenewswire.com
PFE
AMGN
AZN
EVTC
MRK
NVS
Global Dietary Supplements Market to Reach USD 324.88 Billion by 2034 at 6.37% CAGR as Rising Health Consciousness, Preventive Healthcare, Personalized Nutrition, and Growing Demand for Plant-Based Supplements Accelerate Market Growth, Reports Maximize
prnewswire.com
ABT
HRB
PFE
SNY
Spring Health Opens VERA-MH Harm-From-Others Safety Rubric for Public Comment
prnewswire.com
OPEN
MSFT
JPM
TGT
KO
BLK
PFE
Microservices in Healthcare Market Set for Strong Growth Through 2035 as Cloud Adoption, Modular Applications and Digital Transformation Unlock New Opportunities
globenewswire.com
AMZN
MSFT
GOOGL
ORCL
IBM
LLY
PFE
Point-of-Care Molecular Diagnostics Market Poised for Growth Through 2029 as Rapid, Decentralized Testing Drives Opportunities Across Applications, Technologies, Products and Countries
globenewswire.com
ABT
AMGN
DHR
PFE
QGEN
TMO
Global Autoimmune Treatment Market to Reach USD 321.95 Billion by 2034, Driven by Rising Prevalence of Autoimmune Diseases, Growing Adoption of Biologics, and Advances in Precision Medicine Says Maximize Market Research
prnewswire.com
ABBV
JNJ
AMGN
BMY
PFE
NVS
SNY
LLY
AZN
UCB
BIIB
VTRS
GILD
KYMR
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight
globenewswire.com
ABBV
ABCL
AZN
BIIB
BMY
EXEL
GILD
GSK
INCY
LRCX
MRK
NVS
PFE
REGN
SNY
TMO
UCB
VRTX
AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors
globenewswire.com
PFE
NVDA
INM
BTAI
PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment
globenewswire.com
PFE